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A variety of glial cell functions are supported by connexin and pannexin proteins. These
functions include the modulation of synaptic gain, the control of excitability through
regulation of the ion and neurotransmitter composition of the extracellular milieu and
the promotion of neuronal survival. Connexins and pannexins support these functions
through diverse molecular mechanisms, including channel and non-channel functions.
The former comprise the formation of gap junction-mediated networks supported by
connexin intercellular channels and the formation of pore-like membrane structures or
hemichannels formed by both connexins and pannexins. Non-channel functions involve
adhesion properties and the participation in signaling intracellular cascades. Pathological
conditions of the nervous system such as ischemia, neurodegeneration, pathogen
infection, trauma and tumors are characterized by distinctive remodeling of connexin
expression and function. However, whether these changes can be interpreted as part of
the pathogenesis, or as beneficial compensatory effects, remains under debate. Here
we review the available evidence addressing this matter with a special emphasis in
mouse models with selective manipulation of glial connexin and pannexin proteins in vivo.
We postulate that the beneficial vs. detrimental effects of glial connexin remodeling
in pathological conditions depend on the impact of remodeling on the different
connexin and pannexin channel and non-channel functions, on the characteristics of
the inflammatory environment and on the type of interaction among glial cells types.
Keywords: connexins, pannexins, gap junctions, hemichannels, astrocytes, microglia, plasticity
INTRODUCTION
Connexins are transmembrane proteins with a variety of physiological roles including channel
and non-channel functions. Channel functions involve the formation of gap junctions,
which are intercellular connections, permeable to ions and small metabolites, formed by
the apposition of connexin hexamers (connexons) provided by each of the participating cells.
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Gap junction-mediated glial networks are ubiquitous in
the central nervous system and involve astrocytes and
oligodendrocytes. The type of connexins involved in the
interaction depends on the cell types participating in the
connection (Rouach et al., 2002; Giaume and Theis, 2010;
Takeuchi and Suzumura, 2014; Abudara et al., 2018). Connexins
can also function as membrane hemichannels with the potential
to release mediators such as ATP and glutamate from astrocytes
and microglia (Orellana et al., 2013; Gajardo-Gómez et al.,
2016; Nielsen et al., 2017). Non-channel functions of connexins
involve adhesion properties and intracellular cascade signaling
(Zhou and Jiang, 2014; Leithe et al., 2018).
The ubiquitous nature and diversity of connexin functional
properties make them versatile mediators of glial cell physiology
and a putative locus for maladaptive plasticity in pathological
conditions. Plastic changes in abundance and/or functions of
glial connexins have been reported in a variety of pathology
models (Belousov et al., 2017; De Bock et al., 2017; Xing et al.,
2019). However, whether connexin plasticity is causal to the
pathology, or is an epiphenomenon of pathological conditions, is
becoming to be elucidated only recently, owing to the availability
of tools for selective manipulation of glial connexins in vivo
(Giaume and Theis, 2010). Here we review the available work
using rodent models with glia-selective connexin manipulations
to evaluate causal relations between glial connexin plasticity and
neuropathology, focusing on traumatic and neurodegenerative
diseases, ischemia and brain tumors. Most of the cases reviewed
here will focus on connexin 43 (Cx43), which is by far the most
studied glial connexin and dominates the available literature. We
will also review the scarce literature available on glia-selective
pannexin manipulations in these models, and discuss the
glia-selective data in the context of additionally more abundant
data using global connexin and pannexin manipulations.
Modulation of connexin expression and function that may
emerge in the context of hypoxia, inflammation and injury,
both in vitro and in vivo, have been thoroughly reviewed
and putative mechanisms underlying the observed changes
have been proposed (Rouach et al., 2002; Contreras et al.,
2004; Farahani et al., 2005; Kielian, 2008; Orellana et al.,
2009; Eugenin et al., 2012; Koulakoff et al., 2012; Quintanilla
et al., 2012; Bosch and Kielian, 2014; Freitas-Andrade and
Naus, 2016). A few important points emerging from the
body of available literature are worth mentioning before
we focus on glia-selective in vivo manipulations, which is
the focus of this review. The first point is that a change
in connexin immunolabeling needs to be interpreted with
caution. Connexin channels in the context of gap junction
plaques or in a disassembled state can have dramatically
different immunoreactive properties, thus connexins may appear
absent owing to epitope masking (Theriault et al., 1997). This
highlights the importance of using independent approaches
to measure connexin abundance and function. A second
point is that changes in the expression of glial connexins in
pathological conditions are connexin-, time-, region- andmodel-
specific. As an example, Borna virus infection of neonatal
rats results in neurodegeneration and widespread reactivity
of hippocampal astrocytes when analyzed 2 months after
infection (Köster-Patzlaff et al., 2007). This astrocytic activation
is accompanied by an increase of Cx43 in all layers of the
dentate gyrus of the hippocampus and a decrease of the
same connexin in the CA3 pyramidal layer. Another typically
astrocytic connexin, connexin 30 (Cx30), increased in all the
hippocampal regions mentioned above (Köster-Patzlaff et al.,
2007). In contrast, in a mouse model proposed to mimic features
of aging and Alzheimer’s disease induced by ovariectomy and
chronic D-galactose administration, a reduction of Cx43 in
the dentate gyrus and CA1 regions of the hippocampus was
observed, while no change was observed in the CA3 hippocampal
region (Liu et al., 2010). This was suggested to reflect differential
resistance to neuronal damage of CA3 compared to CA1, as
was observed in a model of ischemia in rats (Rami et al.,
2001). Thus, generalizations about connexin plasticity across
brain regions and pathologies should be cautious. A third issue
is that changes in the abundance of glial connexin proteins
in pathological conditions is challenging to interpret without
parallel assessments of functional studies of connexin functions,
such as the extent of gap junction coupling, the permeability
of connexin hemichannels available at the membrane surface
(Sáez et al., 2013) and the phosphorylation state of specific
connexin sites that can mediate intracellular signaling. These
functions may be oppositely modulated and/or have opposing
effects on the severity of the pathology (Retamal et al., 2007;
Karpuk et al., 2011). Therefore, when manipulations target
more than one connexin function—e.g., both gap junctions and
hemichannels—this has to be clearly stated and the effects of
the manipulation should be interpreted with care. Finally, an
important idea, emerging mostly from in vitro studies is that
different connexins are expressed in different cell types of the
nervous system—i.e., neurons, astrocytes, oligodendrocytes and
microglia—and may interact in complex ways when modulated
in pathologic conditions. Even more, glial pannexin proteins,
which form membrane channels showing structure and function
similarity to connexin hemichannels, can also be modulated
in inflammatory conditions and have been proposed to play
a role in pathologic conditions (Freitas-Andrade and Naus,
2016; Lapato and Tiwari-Woodruff, 2018). The contribution
of Cx43 and pannexin-1 (Px1) to hemichannel activity in
astrocytes has been a matter of debate as different studies
assigned a preponderant role to one or the other, depending
on the conditions analyzed (Iglesias et al., 2009; Orellana et al.,
2011). Hence, cell type-selective manipulations of connexins
and pannexins are essential to achieve a comprehensive idea
of their roles in pathology. With these general ideas in
mind, we will review the available literature that aims at
using in vivo selective manipulations of glial connexin and
pannexin functions to address their roles in a subset of
pathologic conditions.
For this purpose, we used keyword search in PubMed
and Scopus citation databases using combinations of keywords
(Table 1). We then reviewed the methods section of all articles
yielded by each search and selected those articles that used
in vivo rodent models. A final selection of work using global and
cell-specific connexin and pannexin manipulations were selected
for detailed analysis.
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TABLE 1 | Number of original research articles found for the keyword







Endothelial + Brain 93 6
Tumor + Brain 212 19
NEURODEGENERATIVE DISEASES
We mentioned that connexins are expressed in different glial
types and may interact in complex ways. To illustrate these
complex interactions, we can mention a study by Orellana
et al. (2011) that addressed the involvement of glial connexins
and pannexins in neuronal death associated with exposure
to a toxic fragment of the amyloid precursor protein, whose
accumulation is associated with Alzheimer’s disease. Orellana
et al. (2011) observed that in cultured cortical astrocytes
and microglia, toxic amyloid fragments increased hemichannel
activity. While astrocyte hemichannel activity was explained
mainly by Cx43 availability, microglial hemichannel activity
involved both Cx43 and Px1 (Orellana et al., 2011). This amyloid-
induced glial hemichannel activity was associated with the
release of metabolites that are toxic for neurons, likely ATP
and glutamate. While microglia-mediated neurotoxicity could be
prevented by combined application of Px1 and Cx43 blockers,
astrocyte-mediated neurotoxicity was abolished by Cx43 block
alone (Orellana et al., 2011). In this same study, hippocampal
slices in organotypic culture exposed to the toxic amyloid
fragment showed increased hemichannel activity. This effect was
revealed by dye uptake first in microglia, then in astrocytes
and finally in neurons. While Cx43 blockers and microglia
inactivation with minocycline completely prevented amyloid-
induced neuronal death, in hippocampal slices obtained from
mice with astrocyte-selective deficiency of Cx43 there was only
a partial protection (Orellana et al., 2011). These data suggest
that astrocytic recruitment is downstream microglial activation,
however, pure astrocyte cultures can produce neurotoxic
conditioned medium in the presence of toxic amyloid fragments.
The relative contributions of microglia and astrocyte connexins
to amyloid-induced neurotoxicity will need microglia-selective
manipulations (Parkhurst et al., 2013; Yona et al., 2013;
Zhao et al., 2019) of connexin and/or pannexin proteins for
further clarification.
It is important to note that amyloid neurotoxicity modeled
in cell and organotypic slice culture systems involve a
rather homogeneous exposure to the toxic fragment. This
homogeneous exposure does not reproduce the neurotoxicity
gradients generated in the pathology characterized by amyloid
deposition in the form of amyloid plaques. The relevance of
these gradients for glial plasticity in Alzheimer’s disease was
nicely illustrated in a mouse model of familial Alzheimer’s
disease (APPswe/PS1dE9 mice, or APP/PS1 mice) characterized
by aging-dependent plaque formation. Hemichannel activity
assessed using dye uptake in acute brain slices was enhanced
in hippocampal astrocytes of APP/PS1 mice when compared
to control mice. Interestingly, hemichannel hyperactivity in
APP/PS1 astrocytes involved Cx43 and Px1 when astrocytes were
located near amyloid plaques, while the increased hemichannel
activity observed in astrocytes far from plaques involved only
Cx43 (Yi et al., 2016). Microglial inhibition by minocycline
partially reduced hemichannel hyperactivity in astrocytes
near plaques, while astrocytes far from plaques remained
unaffected. When the effects of the APP/PS1 mutations on
hemichannel activity were analyzed in the context of a selective
deficiency of Cx43 in astrocytes, almost no hemichannel
activity was observed in astrocytes far from plaques, but
a Px1 component of hemichannel activity remained in
astrocytes near plaques. Thus, Px1 appears to contribute to
astrocyte hemichannel activity in some in vivo conditions (Yi
et al., 2016). Together with the prevention of hemichannel
activity in astrocytes, the astrocyte-selective Cx43 deficiency
in APP/PS1 mice was associated with less mitochondrial
oxidative stress assessed by MitoSOX superoxide indicator
and less dystrophic dendrites, assessed by reticulon 3 (RTN3)
immunoreactivity (Yi et al., 2016), indicating that astrocyte
Cx43 worsened the neurotoxicity of the environment. Of
interest, no differences were observed in indicators of astrocytic
gap junction coupling between APP/PS1 and control mice,
assessed by fluorescence recovery after photobleaching (FRAP;
Yi et al., 2016), strengthening the idea that the neurotoxic
effect of astrocytes was exerted via Cx43 hemichannels.
Further, APP/PS1 mice with astrocyte Cx43 deficiency had
dramatically reduced astrogliosis and improved cognitive
performance compared with APP/PS1 mice. Even more,
re-expression of Cx43 in Cx43-deficient APP/PS1 mice
using an astrocyte-directed adeno-associated viral vector
reinstated the cognitive impairment (Ren et al., 2018).
These results indicate that in the sequence of events of
microglial and astrocytic activation that were proposed to
lead to neuronal damage in Alzheimer’s disease based on
in vitro studies, the increase of Cx43 hemichannel activity in
astrocytes is a deleterious process and this is confirmed in
an in vivo model that selectively manipulates connexins
in astrocytes.
Evidence for the idea that connexins participate in the
complex interaction between astrocytes and microglia during
neuroinflammation was provided as well by studies done
in experimental autoimmune encephalomyelitis, a mouse
model of multiple sclerosis. In this model, the pathologic
condition is produced by subcutaneous immunization with
myelin oligodendrocyte glycoprotein MOG35–55 peptide and
intraperitoneal administration of Pertussis toxin on the day
of immunization and 2 days after (Chen and Brosnan, 2006).
This model is characterized by progressive paralysis followed by
partial remission after an acute peak of clinical signs, associated
with inflammatory infiltrate, demyelination and axonal damage
(Chen and Brosnan, 2006). Mice with a selective astrocytic
Cx43 deficiency or with this deficiency in a global Cx30 knockout
background to prevent compensatory effects were not statistically
different from wild type mice in terms of a clinical score that
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evaluates the severity and time course of the motor signs of
experimental autoimmune encephalomyelitis up to 3–4 weeks
after immunization (Lutz et al., 2012). These mice were not
different either in terms of the degree of immune cell reactivity
in the spinal cord, evaluated using ionized calcium binding
adaptor molecule 1 (Iba1) immunostaining at the endpoint
of clinical evaluation. Interestingly, the global Cx30 deficiency
reduced the severity of the chronic phase (8 weeks after the
insult) in this model and this effect was correlated with the
emergence of an anti-inflammatory phenotype in both spinal
cord astrocytes and microglia (Fang et al., 2018). Given that a
reduction in the abundance of Cx43 during the chronic phase
of experimental autoimmune encephalomyelitis was observed
in global Cx30 deficient mice, the neuroprotective effect could
be mediated indirectly via astrocytic Cx43. This possibility
will need to be specifically tested ideally using conditional
astrocytic-selective and inducible Cx43 deficiency alone or
in combination with Cx30 deficiency. Furthermore, global
Px1 deficiency delayed the onset of symptoms in this model
of experimental autoimmune encephalomyelitis, improving the
clinical state of mice in the acute phase. However, Px1-deficient
mice reached a clinical score that was comparable to the one
observed in wild type mice during the chronic phase (Lutz
et al., 2013). When ATP release was evaluated in the bathing
medium of spinal cord slices, the authors observed that the
enhancement of ATP release that the insult produced was
significantly smaller in slices obtained from Px1-deficient mice
when compared to wild type slices (Lutz et al., 2013). The former
results are compatible with a sequential involvement of Px1 and
Cx30 -and possibly Cx43- in the progression of experimental
autoimmune encephalomyelitis. Further experiments using glial
cell type-selective pannexin and connexin manipulations will
help to determine whether an early microglia dependent
process involving Px1 elicits a late astrocyte-dependent process
involving connexins as part of the pathogenesis of experimental
autoimmune encephalomyelitis.
The importance of connexin and pannexin functions to
explain pathological conditions characterized by neuronal
dysfunction and degeneration is highlighted by data coming
from studies of human diseases linked to connexin and
pannexin mutations. X-linked Charcot-Marie-Tooth disease
type 1 (OMIM #302800) is characterized by progressive muscle
weakness and atrophy associated with mutations in the GJB1
gene, coding for connexin Cx32 (Cx32). These mutations are
linked to peripheral demyelination and axonal degeneration
that can be accompanied by central manifestations (Wang
and Yin, 2016). Deletions of the GJB1 coding sequence in
humans produce a predominantly peripheral phenotype that
is compatible with the alterations observed in Cx32 null
mice (Hahn et al., 2000; Nakagawa et al., 2001). The central
manifestations can be transient, do not appear to correlate
with the severity of peripheral neuropathy and may be
triggered by a variety of stress stimuli (Wang and Yin,
2016). Besides peripheral signs of neuropathy, Cx32 knockout
mice show increased signs of widespread central nervous
system inflammation when compared to wild type mice,
both in basal conditions and after a systemic challenge with
lipopolysaccharide (Olympiou et al., 2016). Interestingly,
Cx32 knockout mice bearing a human Cx32 mutation associated
with central manifestations of X-linked Charcot-Marie-Tooth
disease (Cx32KOT55I) display an enhanced widespread
central nervous system inflammatory response not associated
with oligodendrocyte loss after lipopolysaccharide challenge,
when compared with Cx32 knockout mice that do not carry
this mutation (Olympiou et al., 2016). These data suggest
that Cx32 mutations contribute to the disease not only
through loss-of-function mechanisms that promote central
neuroinflammation in addition to peripheral neuropathy,
but also through gain-of-function mechanisms that increase
the susceptibility to inflammatory challenges. The signals
underlying the enhanced neuroinflammation remain to
be elucidated.
Another demyelinating disease associated with mutations in
the GJC2 gene coding for connexin 47 (Cx47) is Pelizaeus-
Merzbacher-like disease type 1 (OMIM #608804), characterized
by progressive spasticity and ataxia. When compared with
wild type mice, both knockout mice for Cx47 and mice
carrying a mutation associated with the disease in humans
(Cx47KOM282T) show delayed myelination and mild motor
impairment during the juvenile stage, together with cerebellar
astro- and microgliosis, that is no longer observable in the adult
stage owing to compensation by Cx32 (Tress et al., 2011). As
is the case for Cx32-deficient and mutant mice, Cx47-deficient
and mutant mice show evidence of gap junction disassembly, not
only in relation to oligodendrocyte-oligodendrocyte connections
but also for oligodendrocyte-astrocyte connections (Tress
et al., 2011; Olympiou et al., 2016). Whether augmented
signs of neuroinflammation in these connexin-deficient mice
is associated with oligodendrocytic, astrocytic or neuronal
dysfunction, or with a combination of signals from these cell
types, remains to be established.
ISCHEMIA
The question whether astrocytic connexins are beneficial or
detrimental in pathological conditions fueled a rich debate and
is well illustrated for the case of ischemia (Giaume et al., 2007).
Correlational evidence and nonselective manipulations aiming
at inhibition of Cx43 function in astrocytes led to the idea
that Cx43 contributed to the amplification of ischemic damage,
as the treatment with octanol, a nonselective connexin and
gap junction blocker, reduced the infarct size in rat models of
cerebral ischemia by carotid or middle cerebral artery occlusion
(Rawanduzy et al., 1997; Rami et al., 2001).
Contrasting with the former data, in a mouse model of
ischemia produced by middle cerebral artery occlusion during
45 min with evaluation 24 h later, the infarct size was larger
in mice with a selective Cx43 astrocytic deficiency when
compared to wild type mice (Lin et al., 2008). In addition, an
experience of hypoxic preconditioning of 5 h at 8% oxygen
3 days prior to artery occlusion produced an approximate 50%
reduction in infarct size in wild type mice, and was absent
in mice with astrocytic Cx43 deficiency (Lin et al., 2008).
The protective effect of hypoxic preconditioning needed the
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availability of adenosine A1 receptors and it was proposed
to be produced by ATP release by Cx43 hemichannels and
subsequent metabolization to adenosine extracellularly (Lin
et al., 2008). Given that astrocytic Cx43 deficiency is partly
compensated by an increase in Cx30 expression, the mice
used in these experiments were also global Cx30 knockouts
(Wallraff et al., 2006). Cx43 was proposed as pivotal for
neuroprotection in this cerebral ischemia model and was
reinforced by consistent results obtained inmice with conditional
deletion of Cx43 in astrocytes and no deletion of Cx30 (Nakase
et al., 2003). In these mice, more cell death and enhanced
number of inflammatory cells were observed in the area of
penumbra without significant changes in the volume affected
by astrogliosis, when compared with control mice (Nakase
et al., 2004). The protective effect of Cx43 against ischemic
damage was further reinforced by another study using a mouse
line bearing a Cx43 mutation that affects Cx43-mediated gap
junction and hemichannel activity (Gja1Jrt; Kozoriz et al., 2013).
Thus, in contrast to what was observed for the inflammatory
environment of Alzheimer’s disease models, Cx43 was regarded
as neuroprotective under hypoxic conditions. One important
difference called into attention to explain the difference between
these two conditions is the chronicity of the insult in Alzheimer’s
disease models compared to the acute insult in the models
of ischemia.
Genetic models that allow researchers to restrict the connexin
deficiency to specific glial types were a big step forward to address
glial connexin functions in nervous system pathology; however,
there are a series of confounding effects that the strategy does
not address. First, most of the data come from constitutive
lines that tie the connexin deletion of interest to the timing of
expression of a particular promoter, such as the promoter for
glial fibrillary acidic protein (GFAP), which is also expressed by
neural progenitor cells (Giaume and Theis, 2010). This caveat
can be minimized with new tools that spare neural progenitor
cells (Tsai et al., 2012; García-Cáceres et al., 2016; Srinivasan
et al., 2016; Koh et al., 2017) or inducible tools that allow the
researchers to evaluate phenomena in time windows shorter than
the time needed for generation of new neurons (Burns et al.,
2007; Rivers et al., 2008). Second, the deletion of connexin coding
sequences eliminates all connexin functions, thus, it cannot
address hemichannel, gap junction and non-channel connexin
functions separately. This is particularly relevant in light of data
showing that the permeability of gap junction channels and
hemichannels can be oppositely modulated in an in vitro model
of injury in which hemichannels were activated and gap junction
coupling was reduced (Retamal et al., 2007). A promising
tool to dissociate Cx43 hemichannel and gap junction channel
functions is the connexin mimetic peptide Gap19, which blocks
Cx43 hemichannels within the hour after exposure without
affecting Cx43-mediated gap junction coupling. At larger
exposure times, it slightly enhances gap junction coupling, so it
nicely dissociates the two functions (Wang et al., 2013). A recent
study assessed the effects of this peptide in male mice subjected
to a cerebral ischemia-reperfusion protocol (45 min of middle
cerebral artery occlusion and assessment 24 h after initiation
of reperfusion). Intracerebroventricular administration of Gap19
30 min before ischemia had a protective effect, significantly
reducing infarct volume (Chen et al., 2019). This result indicates
that Cx43 hemichannel function is deleterious in ischemia
and suggests that the increase in infarct volume observed in
mice with astrocytic Cx43 deficiency (Nakase et al., 2004)
obeys to a neuroprotective role of Cx43-mediated gap junction
channels that overrides the neurotoxic action of hemichannels.
However, as Gap19 also downregulated Cx43 expression by
about 30% and astrocytic gap junction connectivity was not
assessed (Chen et al., 2019), a contribution of astrocytic gap
junctions to explain the neuroprotective effect of Gap19 cannot
be ruled out. Potential effects of Gap19 in microglia or other
targets could also explain the results, as the manipulation was
not cell-type selective. Further support for the idea that an
increment of astrocytic Cx43 hemichannel activity in response to
ischemic insults is detrimental comes from a study using mice
with global site-directed mutagenesis to eliminate functional
phosphorylation sites that are a substrate for mitogen-activated
protein kinase in the C-terminus of Cx43 (Freitas-Andrade et al.,
2019). These mice (MK4 mice) show reduced infarct size after
permanent middle cerebral artery occlusion when compared
with wild type mice and two other mouse lines targeting
phosphorylation sites for protein kinase C and caseine kinase 1,
these two displaying no protection. Cultured astrocytes from
MK4 mice showed reduced hemichannel activity assessed using
dye uptake and electrophysiological measurements. In addition,
MK4 astrocyte gap junction coupling assessed through a scrape-
loading assay in cortical brain slices was indistinguishably
increased in MK4 and wild type mice after the ischemic insult
(Freitas-Andrade et al., 2019). Given that this was a global
manipulation, it remains to be confirmed that the protective
effect is astrocytic Cx43-dependent.
Non-channel functions of Cx43 involve adhesion properties
and the participation in intracellular signaling via the C-terminal
domain. Cx43 is codified by the Gja1 gene, which can
produce alternative carboxyl-terminal fragments via translation
at alternative initiation sites (Ul-Hussain et al., 2014). Among
these fragments, the GJA1-20k variant is selectively upregulated
in a rat model of brain hypoxia-ischemia and may explain at
least part of the neuroprotective effects produced by Cx43 in
hypoxic conditions. Mice with a C-terminal-truncation in the
Cx43 coding region show more vulnerability to brain ischemia,
however, as astrocytic gap junction and hemichannel functions
are partially disrupted as well in these mice, a neuroprotective
role of the carboxyl-terminal fragment of Cx43, independent
of its impact in channel functions, cannot be confirmed
(Kozoriz et al., 2010).
Multiple connexins and glial types likely contribute to the
outcome after ischemic damage. This idea is reinforced by the
observation that male null mice for Cx32 are more vulnerable
to global cerebral ischemia produced by transient (10 min)
bilateral common carotid artery occlusion (Oguro et al., 2001).
This enhanced vulnerability was observed 7 days after the insult
as increased neuronal loss in the CA1 hippocampal region
of null mice when compared with wild type mice (Oguro
et al., 2001). Given that Cx32 is expressed by oligodendrocytes
and by parvalbumin-positive inhibitory interneurons in the
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hippocampus, the locus of origin of the Cx32-dependent
neuroprotective effect could not be elucidated in this model,
highlighting the need of glia type-selective manipulations of
connexin proteins to address their functions (Doerflinger et al.,
2003; Piantanida et al., 2019).
The contribution of pannexin proteins to the outcome
after ischemic brain damage has been addressed using global
knockout mice for Px1 and pannexin-2 (Px2), two pannexin
proteins expressed in the nervous system. Contrasting with
the deleterious effects of global Cx32 deficiency and astrocytic
Cx43 deficiency, global combined deficiency of Px1 and
Px2 results in protection against ischemic damage when
evaluated 48 h after permanent middle cerebral artery occlusion
(Bargiotas et al., 2011, 2012). Interestingly, astrocytes in primary
culture with combined Px1 and Px2 deficiency show normal ATP
release and membrane conductance, indicating that pannexins
do not contribute significantly to astrocytic channel function
in these in vitro conditions. In contrast, Px1- and Px2-deficient
cortical neurons in primary culture show defective dye release
(Bargiotas et al., 2011). These results suggest that pannexins
contribute to ischemic damage expansion through a neuron-
dependent mechanism. This is supported by a study showing
comparable degrees of protection against ischemia-reperfusion
damage in retinas of global and neuron-selective Px1 deficiency
(Dvoriantchikova et al., 2012). Interestingly, microglial cells
of Px1 deficient mice retain their ability to display rapid
morphologic plasticity in response to extracellular ATP and
other stimuli associated with injury (Dissing-Olesen et al., 2014).
However, a possible contribution of microglia or endothelial
cells (Gaynullina et al., 2014; Sharma et al., 2018) to explain the
neuroprotective effect of global Px1 and Px2 deletion cannot be
ruled out and needs to be specifically tested.
The availability of new mouse lines to achieve conditional
deletion of Px1 using Cre-lox technology (Dvoriantchikova
et al., 2012) and conditional expression of tamoxifen-inducible
Cre recombinase in microglia and leptomeninges, sparing
blood monocytes (Kaiser and Feng, 2019) is much promising.
Given that Px2 can compensate for Px1 deficiency, and
vice versa (Bargiotas et al., 2011) an in vivo approach
to address the impact of microglia-selective Px1 deficiency
on ischemic damage and other pathologic conditions will
likely need to combine the conditional microglia-selective
Px1 deletion with a global (or conditional, when available)
Px2 deletion. This is an analogous strategy to the one used
to address the roles of astrocytic Cx43 without compensation
by Cx30 (Wallraff et al., 2006). One additional factor that
has to be taken into consideration is the observation of
sexual dimorphism in the neuroprotective effect of global
Px1 deficiency. When evaluated 48 h after middle cerebral artery
occlusion without sex discrimination, global Px1 deficiency
did not show protection against ischemic damage (Bargiotas
et al., 2011). Of note, another study using a middle cerebral
artery occlusion lesion model in an independently generated
Px1-knockout line observed that females with Px1 deficiency
showed approximately 50% smaller size infarcts 4 days after
the lesion when compared with wild type females (Freitas-
Andrade et al., 2017). In contrast, males with Px1 deficiency
displayed lesion sizes that were indistinguishable from lesions
in wild type male mice. The differential susceptibility to
ischemic damage between males and females correlated with
differential astrocytic reactivity and degree of neuroinflamation,
assessed through GFAP and Iba1 immunostaining, respectively,
which were less dramatic in Px1-deficient female mice when
compared to wild type female mice and males of either genotype
(Freitas-Andrade et al., 2017). These data highlight the need
to analyze the possibility for sexually dimorphic responses
to nervous system insults before concluding a lack of effect
of manipulations.
Overall, the current available data strongly suggest that
therapeutic interventions to prevent ischemic damage will benefit
from strengthening the efforts to develop tools to counteract
connexin and pannexin hemichannel activity while preserving
connexin gap junction function.
SPINAL CORD INJURY
Female mice with selective astrocytic Cx43 deficiency in a
Cx30-knockout background were also assessed to evaluate their
response to spinal cord contusion injury, and compared to
controls that had only the global Cx30 deficiency (Huang
et al., 2012). This study reported that the response to
weight-drop spinal cord injury involved less ATP release
in the peritraumatic area 1 h after injury in mice with
astrocytic Cx43 deficiency. These mice also showed reduced
astrocytic and microglial reactivity 1 week after injury and
smaller lesion sizes than control mice when evaluated 8 weeks
after injury, accompanied by an improved functional recovery
that was observed as early as 3 days after damage (Huang
et al., 2012). Thus, in this injury model, Cx43 availability
was deleterious. In another model of spinal cord contusion
injury in rats, peptide5, a Cx43 mimetic peptide that blocks
Cx43 hemichannels and gap junctions (O’Carroll et al.,
2008), administered at the lesion site 1 h after the lesion,
diminished astrocytic activation and inflammatory cell numbers
at the lesion site, promoted neuronal survival, and improved
locomotor recovery when compared with the administration
of a control peptide (O’Carroll et al., 2013). These data
are consistent with the more selective astrocyte-directed
manipulation of Cx43 mentioned above and support the idea
that Cx43 is deleterious for the outcome of traumatic spinal
cord injury. Interestingly, comparable results were obtained
when peptide5 was administered systemically to rats with
spinal cord contusion (Mao et al., 2017b). Consistent results
were obtained in yet another study using female mice treated
systemically with INI-0602, a derivative of the broadly used
non-selective connexin and pannexin blocker carbenoxolone
(Bruzzone et al., 2005; Dahl et al., 2013), that prevents the
release of glutamate from mouse cultured microglia in response
to lipopolysaccharide administration (Takeuchi et al., 2011).
Administration of INI-0602, starting at the time of injury
and during a month, improved the outcome of transection
spinal cord injury, reducing astrogliosis and inflammation,
and improving motor recovery (Umebayashi et al., 2014).
These results emphasize the idea that even when cell-type
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selective manipulations are essential to address the mechanisms
behind the resolution of injuries, non-selective manipulations
have potential as useful treatments, provided that there are
no significant undesired off-targets for the therapeutic agent
(Mao et al., 2017a).
In contrast to what was reported in spinal cord injury
models, mice with astrocytic Cx43 deletion in a wild type
Cx30 background increased the extent of astrogliosis and
inflammatory cells around the lesioned area in a brain stab
wound injurymodel (Theodoric et al., 2012). A number of factors
may explain these differences, such as the type of injury, the
lesion site, the time of observation after injury and the cellular
microenvironment around the wound.
NEUROPATHIC PAIN
The development of neuropathic pain after peripheral or central
damage involves plastic changes in spinal nociceptive circuits
that involve glial plasticity as well. Selective manipulation
of astrocytes and microglia have recently revealed that
connexin and pannexin proteins in these glial types are
critical for the development of neuropathic pain. In a
mouse model of mild spinal cord injury, selective astrocytic
Cx43 deficiency in a Cx30 knockout background reduced the
development of mechanical allodynia and heat hyperalgesia,
when compared with Cx30 knockout and wild type mice
(Chen et al., 2012). On the other hand, Px1 deficiency in
myeloid cells including microglia attenuated the development
of mechanical allodynia in a model of induced osteoarthritis
by intra-articular administration of monosodium iodoacetate.
Interestingly, the hyperactivity of spinal dorsal horn neurons
associated with the development of mechanical allodynia
was also attenuated by myeloid cell-selective deletion of
Px1 (Mousseau et al., 2018). It is important to note that
this study used an inducible knock-in/knock-out Cre-lox
system that allowed the researchers to evaluate the acute
effects of eliminating Px1 expression in the myeloid lineage.
Another study used a model in which mechanical allodynia
also develops after spared nerve injury of the sciatic nerve.
This study did not observe a reduction of pain thresholds
in mice with Px1 deficiency in the myeloid lineage using a
non-inducible transgenic Cre-lox system under comparable
regulatory sequences (the Cx3cr1 promoter; Weaver et al., 2017).
In contrast, this same study did observe a prevention of nerve
injury-induced mechanical allodynia in global Px1-deficient
mice. These results suggest that the non-inducible deletion of
Px1 from myeloid cells can be developmentally compensated,
while the global Px1 deletion cannot. Strikingly, Weaver
et al. could reinstate the capability for nerve injury-induced
mechanical allodynia in global Px1-deficient mice after
wild type bone marrow transplantation, indicating that
bone marrow-derived immune cells confer at least part of
the Px1 dependence of nerve injury-induced mechanical
allodynia. Combined manipulations of astrocytic connexins and
microglial pannexins in specific time windows will help elucidate
whether and how these cell types and molecules interact
for the development of neuropathic pain. The availability
of tools to genetically manipulate astrocytes and microglia
with different inductor drugs (Tanaka et al., 2012; Srinivasan
et al., 2016) is a promising new avenue with potential to
assess interactions between these cell types. The generation
of new tools designed to achieve targeted deletions of a
broader diversity of connexins and pannexins than what is
available (Liao et al., 2001; Cohen-Salmon et al., 2002; Poon
et al., 2014; Clasadonte et al., 2017) will overcome one of the
current limitations.
TUMORS
Besides their participation in the resolution of nervous system
damage, astrocytes are determinants of the microenvironment
in which brain tumors develop. In addition, tumor cells
express connexins and there is evidence using dye transfer
in vitro and in vivo that they can establish connexin-mediated
gap junctions with non-tumor cells (Zhang et al., 1999,
2003). However, a direct electrophysiological measurement of
gap junction coupling between astrocytes and tumor cells
is still lacking. Data supporting the relevance of connexin
proteins as potential targets for antitumor therapy have been
reviewed recently (Aasen et al., 2017; Umans and Sontheimer,
2018; Uzu et al., 2018). Whether connexin gap junction,
hemichannel and/or non-channel functions are important for
tumor progression has not been resolved. However, there
is compelling evidence that some tumor cells downregulate
connexin proteins and that restoring connexin expression
reduces malignancy. As an example, C6 rat glioma cells express
low levels of Cx43 and Cx30. When implanted intracranially,
they produce well-defined large tumors in the brain parenchyma,
resulting in a survival rate of 43% of transplanted individuals
after 30 days of implantation. However, rats implanted with Cx30
cDNA-transfected C6 glioma cells exhibited 66% of survival
rate, and smaller tumor masses were detected by MRI analysis
(Arun et al., 2017). Interestingly, Px1-transfected C6 glioma
cells in culture showed reduced proliferation and motility
and displayed dye coupling, which was virtually absent in
untransfected C6 cells (Lai et al., 2007). When inoculated to nude
mice, Px1-transfected C6 glioma cells produced significantly
smaller tumors than cells transfected with a control construct.
Similar results were observed for Px2-transfected C6 glioma cells
(Lai et al., 2009).
Contrasting with the former results, in a brain metastasis
model using nude mice inoculated with mammary
adenocarcinoma cells of human origin via the left cardiac
ventricle, shRNA-mediated depletion of Cx43 from cancerous
cells reduced metastatic growth in the brain parenchyma when
assessed 2 weeks after inoculation (Chen et al., 2016, 2017).
Wild-type Cx43 re-expression in Cx43-depleted cancerous
cells rescued metastatic activity, whereas re-expression of
a mutated variant of Cx43 that does not form functional
channels [Cx43(T154A)] did not (Beahm et al., 2006).
Interestingly, Cx43 promoted proliferation of metastatic
cells in the brain, but not extravasation across the blood-
brain barrier, as Cx43 depletion in cancer cells did not
significantly diminish the number of cancer cells in the
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FIGURE 1 | Summary of the impact of global and astrocyte-selective connexin function disruption in the context of in vivo models of central nervous
system disease.
brain parenchyma, but micrometastases showed decreased
proliferative activity when assessed 1 week after cancer cell
inoculation. Based on a large body of accompanying in vitro
data, the authors proposed a model in which gap junctions
between tumor cells and astrocytes are required for cancer
cell growth and survival (Chen et al., 2016). However, a
potential hemichannel function of Cx43 in this process cannot
be discarded.
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FIGURE 2 | Summary of the impact of global and myeloid cell-selective pannexin function disruption in the context of in vivo models of central nervous
system disease.
Further research with in vivo models and tumor cell
manipulations targeting specific connexin functions will shed
light on the roles of connexins expressed by cancer cells for
their capacity to invade the brain parenchyma, their proliferation
and survival, which may differ depending on cancer cell
type. To conclude, we will focus on the analysis of plasticity
of astrocyte connexin functions in the proximity of tumor
cells and their possible detrimental or beneficial effects for
tumor progression.
In mice with Cx43-deficient astrocytes, brain implantation
of mouse GL261 glioma cells resulted in a larger extent of
astrogliosis near the tumor implant, together with reduced
invasion of tumor cells into the brain parenchyma. This
result was replicated when Cx43-knockdown glioma cells
were implanted in wild type mice (Sin et al., 2016). To
determine which Cx43 function was taking part in this
process, glioma cells were transfected with cDNA coding
for the channel-defective Cx43 mutant variant, Cx43(T154A),
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Construct Induction method RRID Reference
Astrocytes Aldh1l1-Cre/ERT2 BAC
transgene
Tamoxifen IMSR_JAX:029655 Srinivasan et al. (2016)
Astrocytes, adult neural
progenitors cells










PLP1-Cre/ERT transgene Tamoxifen IMSR_JAX:005975 Doerflinger et al. (2003),
Guo et al. (2010) and





Tamoxifen IMSR_JAX:008538 Zhu et al. (2011)
Microglia, mononuclear
phagocyte system






Tamoxifen IMSR_JAX:021160 Parkhurst et al. (2013)
Microglia, mononuclear
phagocyte system























AAV(5)-GFAP(2.2)-iCre Cre recombinase García-Cáceres et al. (2016)
Astrocytes AAV-DJ-hALDH1L1-Cre Cre recombinase Koh et al. (2017)
Connexin and pannexin floxed lines
Targeted gene Targeted sequence Targeted
connexins
RRID Reference
Gja1 Exon 2 Cx43 IMSR_JAX:008039 Liao et al. (2001) and
Clasadonte et al. (2017)
Gjb2 Exon 2 Cx26 Cohen-Salmon et al. (2002)
Panx1 Exon 3/4 Px1 Dvoriantchikova et al.
(2012) and Poon et al.
(2014)
and implanted in astrocyte-selective Cx43-deficient mice,
or control mice. Tumor invasion was compromised only
in the astrocyte Cx43 null background, suggesting that
heterocellular (glioma-astrocyte) gap junction channel
activity is not necessary for tumor invasion. However,
release of astrocyte gliotransmitters via Cx43 hemichannels
cannot be discarded. In addition, the outcome of implanted
glioma cells was assessed in Cx43∆CT/− mice carrying one
astrocyte-selective null Cx43 allele and one ∆CT allele that
consists in a truncated Cx43 variant (Cx43K258stop). This
variant lacks a cytoplasmic tail that carries phosphorylation
sites and protein-interacting domains (Freitas-Andrade
et al., 2019) and exhibits reduced gap junction activity and
increased hemichannel activity when assessed in cultured
astrocytes using dye transfer and uptake techniques (Sin et al.,
2016). Cx43∆CT/− mice displayed compromised invasion
of tumor cells in the brain parenchyma and increased
astrogliosis when compared with Cx43+/− (mice carrying
one astrocyte-selective Cx43 null allele and one wild type
allele; Sin et al., 2016). These results indicate that astrocytic
Cx43 constitutes a means for tumor invasion in the brain.
The channel and non-channel functions directly involved
in tumor invasion and survival are still elusive; however, at
least in the former case, the results seem to discard adhesive
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properties of the extracellular loops, which remained intact
in the mutant variants used, provided that Cx43 expression
levels and traffic to the membrane remained invariant.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
A summary of the cases of connexin- and pannexin-deficient
mouse models reviewed is shown in Figures 1, 2. One interesting
feature to highlight is that astrogliosis appears dissociated
from the availability of functional astrocytic connexins and
is likely more related with the inflammatory environment
associated with each particular case. The data reviewed
gives support to the idea that the hyperactivation of glial
hemichannels leads to circuit dysfunction and worsens
neurodegeneration in a variety of contexts. The generally
beneficial effect of pannexin deficiency vs. the more variable
outcomes observed for connexin deficiency supports the idea
that connexin proteins can form both hemichannels and gap
junctions, while pannexin proteins are predominantly identified
with hemichannel function. Efforts to develop blood-brain
barrier-permeant connexin hemichannel blockers for systemic
administration appear as promising therapeutic tools. Tools
to favor the bias of connexins towards gap junction assembly
at the expense of hemichannel availability are expected to
be beneficial.
Future studies exploiting the advantages of cell-type
specific connexin and/or pannexin disruption, time control
provided by inducible genetic drivers or vector administration
(Table 2) and dissociated manipulation of gap junction
channel, hemichannel and non-channel functions will
contribute to address the roles of connexins in different
nervous system pathologies to better design adequate
therapeutic interventions. The focus on cell types whose
roles are only beginning to be explored as participants in
neuroinflammation (Table 1) is a fertile field for new research.
One interesting case is NG2 glia, known to be precursors of
mature oligondendrocytes present in numbers comparable
to astrocytes in many brain areas (Nishiyama et al., 2005)
and to be components of the glial scar after traumatic injury
(Schäfer and Tegeder, 2018). Of particular importance is the
availability of genetic tools to manipulate NG2 glia selectively
(Zhu et al., 2011).
In addition, forthcoming studies will need to address
complex interactions arising from combined selective connexin
deficiency in more than one cell type. We should not be
surprised by finding regional, age and pathology-dependent
differences instead of a more general rule. Figures 1, 2
highlight the complexity of drawing unequivocal conclusions
regarding the relevance of hemichannel, gap junction and
non-channel functions of connexins and pannexins. Despite
the availability of a substantial diversity of genetic tools to
distinguish among these functions, it is uncommon to find
comparisons of their effects in the same disease model with
experiments run in parallel to minimize factors of variability.
We envision that collaborative work of different groups with
the aim of shedding light on this question will generate
invaluable new and confirmative data crucial for the design of
new therapies.
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